


EXHIBIT C

Applicant: David Baltimore et al.
Serial No.: 10/037,415
Filed: January 4, 2002

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002 | Page 1 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation
						Yes
						No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	June 9, 2006 Complaint, <i>Ariad Pharmaceuticals, Inc.</i> v. Jon W. Dudas, Civil Action 1:06cv679 (CMH/BRP)
	July 12, 2006 Notice of Hearing, <i>Ariad Pharmaceuticals, Inc.</i> v. Jon W. Dudas, Civil Action 1:06cv679 (CMH/BRP)
	August 2, 2006 Memorandum Of Law In Support Of Defendant's Motion To Dismiss Or In The Alternative For Summary Judgement And Opposition To Plaintiffs' Motion For Summary Judgment, <i>Ariad Pharmaceuticals, Inc.</i> v. Jon W. Dudas, Civil Action 1:06cv679 (CMH/BRP)
	August 2, 2006 Statement Regarding Eli Lilly & Company's Motion To Intervene And For Leave To File, <i>Ariad Pharmaceuticals, Inc.</i> v. Jon W. Dudas, Civil Action 1:06cv679 (CMH/BRP)
	August 14, 2006 Notice Of Filing, <i>Ariad Pharmaceuticals, Inc.</i> v. Jon W. Dudas, Civil Action 1:06cv679 (CMH/BRP)
	August 14, 2006 Plaintiffs' Brief in Opposition To Motion To Intervene By Eli Lilly and Company, <i>Ariad Pharmaceuticals, Inc.</i> v. Jon W. Dudas, Civil Action 1:06cv679 (CMH/BRP)
	August 14, 2006 Plaintiffs' Brief In Reply To Defendant's Motion To Dismiss Or In the Alternative For Summary Judgment And

EXAMINER

DATE CONSIDERED

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 75723-ZB/JPW/GJG		Serial No. 10/037,415
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants David Baltimore et al.		
					Filing Date January 4, 2002		Page 2 of 50
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Opposition To Plaintiffs' Motion For Summary Judgment, <i>Ariad Pharmaceuticals, Inc.</i> v. Jon W. Dudas, Civil Action 1:06cv679 (CMH/BRP)					
		August 28, 2006 Reply Memorandum In Support Of Defendant's Motion To Dismiss, Or, In the Alternative, For Summary Judgment, <i>Ariad Pharmaceuticals, Inc.</i> v. Jon W. Dudas, Civil Action 1:06cv679					
		October 3, 2006 Order (Defendant's Motion to Dismiss), <i>Ariad Pharmaceuticals, Inc.</i> v. Jon W. Dudas, Civil Action 1:06cv679					
		October 3, 2006 Order (Eli Lilly & Company's Motion to Intervene), <i>Ariad Pharmaceuticals, Inc.</i> v. Jon W. Dudas, Civil Action 1:06cv679					
		August 2, 2006 Defendant Eli Lilly And Company's Pre-Trial Brief, <i>Ariad Pharmaceuticals, Inc.</i> v. <i>Eli Lilly and Company</i> , Civil Case 02 CV 11280 RWZ					
		August 2, 2006 Plaintiffs' Supplemental Trial Brief, <i>Ariad Pharmaceuticals, Inc.</i> v. <i>Eli Lilly and Company</i> , Civil Case 02 CV 11280 RWZ					
		September 11, 2006 Plaintiffs' Proposed Findings of Fact and Conclusions of Law on the issues of Inequitable Conduct,					
EXAMINER		DATE CONSIDERED					
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 3 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Indefiniteness, Prosecution Laches, and Non-Patentable Subject Matter, <i>Ariad Pharmaceuticals, Inc. V. Eli Lilly and Company</i> , Civil Case 02 CV 11280 RWZ
	September 11, 2006 Lilly's Post-Trial Proposed Findings Of Fact And Conclusions Of Law Relating To (1) Invalidity Under 35 U.S.C. §101, (2) Unenforceability For Inequitable Conduct, And (3) Unenforceability For Prosecution Laches, <i>Ariad Pharmaceuticals, Inc. V. Eli Lilly and Company</i> , Civil Case 02 CV 11280 RWZ
	September 29, 2006 Plaintiffs' Reply To Lilly's Proposed Findings of Fact And Conclusions of Law On the Issues of (1) Patentability Under 35 U.S.C. §010, (2) Inequitable Conduct, and (3) Prosecution Laches, <i>Ariad Pharmaceuticals, Inc. V. Eli Lilly and Company</i> , Civil Case 02 CV 11280 RWZ
	September 29, 2006 Lilly's Response To Ariad's Proposed Findings of Facts And Conclusions of Law, <i>Ariad Pharmaceuticals, Inc. V. Eli Lilly and Company</i> , Civil Case 02 CV 11280 RWZ
	April 20, 2006 Complaint For Declaratory Judgment Of Patent Invalidity And Non-Infringement, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action No.
	April 20, 2006 Civil Cover Sheet, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action CA

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002 | Page 4 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation
							Yes
							No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		April 20, 2006 Report On The Filing or Determination of an Action Regarding a Patent or Trademark, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action CA 06-259
		June 14, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Motion To Dismiss For Lack of Subject Matter Jurisdiction, Failure To State a Claim, And Failure To Join Indispensable Parties, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
		June 14, 2006 Declaration of Laurie A. Allen (including Exhibits A-D), <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
		June 14, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Opening Memorandum of Law In Support Of Its Motion To Dismiss For Lack of Subject Matter Jurisdiction, Failure To State A Claim For which Relief May Be Granted, And Failure To Join Indispensable Parties (including Tab 1), <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
		June 28, 2006 Declaration of Paul Cantrell, Esq. Signed May 18, 2006, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action No. 1:06-cv-259 (KAJ)
		June 28, 2006 Declaration of Melanie K. Sharp (including Exhibits A-L), <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action No. 1:06-cv-259 (KAJ)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 5 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	June 26, 2006 Declaration of Frank Ungemach (including Exhibits A-H), <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action No. 1:06-cv-259 (KAJ)
	June 28, 2006 Plaintiffs' Opposition To Ariad's Motion To Dismiss For Lack of Subject Matter Jurisdiction, Failure To State a Claim, And Failure to Join Indispensable Parties (including Exhibits A-D unreported cases), <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
	July 12, 2006 Declaration of Fritz Casselman, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
	July 13, 2006 Declaration of Patricia Carson, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
	July 13, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Reply Memorandum of Law In Support of its Motion to Dismiss For Lack of Subject Matter Jurisdiction, Failure to State a Claim For Which Relief May Be Granted, And Failure To Join Necessary And Indispensable Parties, <i>Amgen, Inc.</i>
	July 12, 2006 Supplemental Declaration of Laurie A. Allen, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 6 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Proposed Final Pretrial Order, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
	July 19, 2006 Scheduling Order, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
	July 19, 2006 Trial Management Order, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
	July 21, 2006 Letter to Judge Jordan from Melanie K. Sharp of Young Conaway Stargatt & Taylor, LLP, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
	July 25, 2006 Letter to Judge Jordan from Steven J. Balick of Ashby & Geddes, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
	August 30, 2006 Letter to Judge Jordan from Steven J. Balick of Ashby & Geddes (including Exhibits A & B), <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
	August 31, 2006 Letter to Judge Jordan from Melanie K. Sharp of Young Conaway Stargatt & Taylor, LLP (including Exhibits 1 & 2), <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicants

David Baltimore et al.

Filing Date

January 4, 2002

Page 7 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation
						Yes
						No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	September 13, 2006 Order, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
	September 25, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Motion Certification Pursuant to 28 U.S.C. §1292(b), <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
	September 25, 2006 Defendant Ariad Pharmaceuticals Inc.'s Opening Memorandum of Law In Support of Its Motion For Certification Pursuant To 28 U.S.C. §1292(b), <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
	September 25, 2006 Ariad Pharmaceuticals, Inc.'s Answer To Compliant, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
	September 25, 2006 Declaration of Elizabeth L. Rosenblatt In Support of Ariad Pharmaceuticals, Inc.'s Motion For Certification Pursuant To 28 U.S.C. §1292(b) (including Exhibits A-Q), <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
	October 2, 2006 Ariad Opposition Ex. A-C, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 8 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation
							Yes
							No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		October 10, 2006 Plaintiffs' Memorandum in Opposition To Ariad's Motion For Certification Pursuant to 28 U.S.C. §1292(b), <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
		October 10, 2006 Amgen Appendix of Exhibits 1-2 To Plaintiffs' Memorandum in Opposition To Ariad's Motion For Certification Pursuant to 28 U.S.C. §1292(B), <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
		October 12, 2006 Order, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
		October 17, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Reply Memorandum of Law In Support Of Its Motion For Certification Pursuant To 28 U.S.C. §1292(b), <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
		November 3, 2006 Order, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
		July 7, 2006 Plaintiffs' First Set of Interrogatories to Defendant, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
		July 7, 2006 Plaintiffs' First Set of Requests for Production of Documents and Things to Defendant, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 9 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation
						Yes
						No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	July 26, 2006 Defendant's Rule 26(a)(1) Initial Disclosure, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
	July 26, 2006 Plaintiffs' Initial Disclosures Pursuant to Federal Rule of Civil Procedure 26(a)(1), <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
	August 7, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Responses And Objections to Plaintiffs' First Set of Requests For Production of Documents and Things to Defendant, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
	September 27, 2006 Defendant Ariad Pharmaceuticals, Inc.'s First Supplemental Responses And Objections To Plaintiffs' First Set of Requests for Production of Documents And Things to Defendant, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
	August 7, 2006 Defendant Ariad Pharmaceuticals, Inc.'s Responses And Objections To Plaintiff Amgen, Inc.'s First Set of Interrogatories to Defendant, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ
	September 27, 2006 Defendant Ariad Pharmaceuticals, Inc.'s First Supplemental Responses and Objections To Plaintiffs' First Set Of

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office				Atty. Docket No. 75723-ZB/JPW/GJG		Serial No. 10/037,415	
						Applicants David Baltimore et al.			
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)						Filing Date January 4, 2002	Page 10 of 50		
U.S. PATENT DOCUMENTS									
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate		
FOREIGN PATENT DOCUMENTS									
		Document Number	Date	Country	Class	Subclass	Translation		
							Yes	No	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									
		Requests for Production of Documents and Things to Defendant, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ							
		October 11, 2006 Defendant Ariad Pharmaceuticals, Inc.'s First Supplemental Responses and Objections to Plaintiff Amgen, Inc.'s First Set of Interrogatories to Defendant, <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ							
		October 26, 2006 Stipulated Protective Order Pursuant To Federal Rule of Civil Procedure 26(c), <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ							
		July 12, 2006 Telephone Conference before Honorable Kent A. Jordan, U.S.D.C.J., <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ							
		September 11, 2006 Motions Hearing before Honorable Kent A. Jordan, U.S.D.C.J., <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ							
		November 3, 2006 Motion Hearing before Honorable Kent A. Jordan, U.S.D.C.J., <i>Amgen, Inc. V. Ariad Pharmaceuticals, Inc.</i> , Civil Action 06-259-KAJ							
EXAMINER			DATE CONSIDERED						
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>									

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Applicants David Baltimore et al.

Filing Date
January 4, 2002

Page 11 of 50

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		January 22, 2007 Declaration of Elizabeth L. Rosenblatt in Support of Ariad Pharma., Inc.'s Motion to Stay Litigation Pending Conclusion of Reexamination Proceedings in the Patent and Trademark Office, Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-*** (MPT)	
		January 23, 2007 Defendant Ariad Pharma., Inc.'s Motion to Stay Litigation Pending Conclusion of Reexamination Proceedings in the Patent and Trademark Office, Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-*** (MPT)	
		January 23, 2007 Defendant Ariad Pharma., Inc.'s Opening Memorandum of Law in Support of Its Motion to Stay Litigation Pending Conclusion of Reexamination Proceedings in the Patent and Trademark Office (including Exhibits A-G), Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-*** (MPT)	
		January 31, 2007 Plaintiffs' First Set of Requests for Admission to Defendant, Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259 (***)	
		February 20, 2007 Transcript of Oral Argument Hearing before Hon. Mary Pat Thynge, U.S. Magistrate Judge, Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259 (***)	
		February 22, 2007 Defendant Ariad Pharma., Inc.'s First Set of Requests for Production of Documents, Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-MPT	
		February 22, 2007 Defendant Ariad Pharma., Inc.'s First Set of Interrogatories, Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-MPT	
		March 7, 2007 Defendant Ariad Pharma., Inc.'s Responses and Objections to Plaintiffs' First Set of Requests for Admission to Defendant, Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-MPT	
		March 26, 2007 Plaintiffs' Responses to Defendant's First Set of Requests for Production of Documents, Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-MPT	
		March 26, 2007 Plaintiffs' Responses and Objections to Ariad's First Set of Interrogatories, Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-MPT	

EXAMINER
SIGNATURE

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants David Baltimore et al.
Filing Date
January 4, 2002

Page 12 of 50

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		April 3, 2007 Plaintiffs' Multi-Media Materials (Technology Tutorial), Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-MPT	
		April 3, 2007 Notice of Filing of Multi-Media Materials (Plaintiffs' Technology Tutorial), Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-MPT	
		April 3, 2007 Notice of Filing of Multimedia Materials (including Tabs A and B), Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-MPT	
		April 3, 2007 Ariad Pharma., Inc. Technology Tutorial, Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-MPT	
		April 12, 2007 Defendant Ariad Pharma., Inc.'s Second Supplemental Responses and Objections to Plaintiffs' First Set of Interrogatories to Defendant, Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-MPT	
		April 13, 2007 Amended Complaint for Declaratory Judgment of Patent Invalidity and Non-Infringement, Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-MPT	
		April 13, 2007 Second Amended Complaint for Declaratory Judgment of Patent Invalidity and Non-Infringement, and Unenforceability, Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-MPT	
		April 13, 2007 Answer to Amended Complaint, Counterclaim and Demand for Jury Trial, Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-MPT	
		April 17, 2007 Letter to Judge Thynge from Steven J. Balick, Esq., Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-MPT	
		April 19, 2007 Defendant and Counterclaim Plaintiff Ariad's Second Set of Requests for Production of Documents to Amgen, Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-MPT	
		April 20, 2007 Defendant Ariad Pharma., Inc.'s First Supplemental Responses and Objections to Plaintiffs' First Set of Requests for Admission to Defendant, Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-MPT	
		April 23, 2007 Plaintiffs' First Supplemental Responses and Objections to Ariad's First Set of Interrogatories, Amgen, Inc. et al. v. Ariad Pharma., Inc., CA No. 06-259-MPT	

EXAMINER
SIGNATURE

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicants David Baltimore et al.

Filing Date January 4, 2002 Page 13 of 50

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		May 1, 2007 Amgen's Technology Tutorial, <i>Amgen, Inc. et al. v. Ariad Pharma., Inc.</i> , CA No. 06-259-MPT	
		May 1, 2007 Ariad Pharma., Inc. Technology Tutorial, <i>Amgen, Inc. et al. v. Ariad Pharma., Inc.</i> , CA No. 06-259-MPT	
		May 1, 2007 Transcript of Tutorial Hearing before Hon. Mary Pat Thyng, U.S. Magistrate Judge, <i>Amgen, Inc. et al. v. Ariad Pharma., Inc.</i> , CA No. 06-259-MPT	
		May 3, 2007 Amgen Entities' Reply to Ariad, Harvard, MIT, and Whitehead's Counterclaim, <i>Amgen, Inc. et al. v. Ariad Pharma., Inc.</i> , CA No. 06-259-MPT	
		Bottero et al. (2006) "NF-κB and the regulation of hematopoiesis," <i>Cell Death and Differentiation</i> , 13: 785-797	
		Doucas et al. (2000) "Cytoplasmic catalytic subunit of protein kinase A mediates cross-repression by NF-κB and the glucocorticoid receptor," <i>PNAS</i> , 97(22): 11893-11898	
		Withoff, S. et al. "Regulating the Master Regulator NF-κB: From Natural Strategies to Rationally Designed Superdrugs." in: Ghosh, S., <i>Handbook of Transcription Factor NF-kappaB</i> (Boca Raton, FL, CRC Press, 2007), pp. 195-211	

EXAMINER
SIGNATURE

¹EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³Applicant is to place a checkmark here if English language Translation is attached.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 14 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Berry et al., "1 α , 25-Dihydroxyvitamin D ₃ Stimulates Phosphorylation of I κ B α and Synergizes with TPA to Induce Nuclear Translocation of NF κ B during Monocytic Differentiation of NB4 Leukemia Cells, Experimental Cell Research 272, 176-184 (2002)
	Lepper et al., "Clinical implications of antibiotic-induced endotoxin release in septic shock", Intensive Care Med (2002), 28:824-833
	Shenep and Mogan, "Kinetics of Endotoxin Relaese During Antibiotic Therapy For Experimental Gram-Negative Bacterial Sepsis", The Journal of Infectious Diseases, Vol. 150, No. 3, (1984) 380-388
	July 6, 2007 Finding of Facts And Conclusions of Law, Ariad Pharmaceuticals, Inc. v. Eli-Lilly & Co., U.S. District Court, District of Massachusetts, CV-02-11280-RWZ

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 15 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	April 17, 2007 Deposition of Harvey J. Berger, M.D., Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	April 20, 2007 Videotaped Deposition of Chen-Ming Fan, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	April 24, 2007 Videotaped Deposition of Jonathan H. Lebowitz, Ph.D., Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	April 27, 2007 Videotaped Deposition of Harinder Singh, Ph.D., Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	May 3, 2007 Videotaped Deposition of Ranjan Sen, Ph.D., Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	May 16, 2007 Videotaped Deposition of Phillip A. Sharp, Ph.D., Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 16 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	May 25, 2007 Videotaped Deposition of Albert S. Baldwin, Jr., Ph.D., Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	June 7, 2007 Videotaped Deposition of Michael J. Lenardo, M.D., Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	May 8, 2007 Defendant Ariad Pharmaceuticals, Inc.'s Third Supplemental Responses and Objections To Plaintiffs' First Set Of Interrogatories To Defendant, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	May 30, 2007 Defendant Ariad Pharmaceuticals, Inc.'s Second Supplemental Responses And Objections To Plaintiff's First Set of Requests For Admission To Defendant, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	May 30, 2007 letter to Judge Thynge from Melanie K. Sharp of Young Conaway Stargatt & Taylor, LLP, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Applicants

David Baltimore et al.

Filing Date

January 4, 2002

Page 17 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	May 31, 2007 letter to Judge Thynge from Steven J. Balick of Ashby & Geddes, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	June 5, 2007 Wyeth's Reply To Ariad Pharmaceuticals, Inc., Massachusetts Institute of Technology, The President And Fellows of Harvard College, and The Whitehead Institute for Biomedical Research's Counterclaim, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	June 14, 2007 Amgen Entities' Second Supplemental Responses And Objections To Ariad's First Set of Interrogatories: NOS. 1, 2, 5, 6 & 12, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	Abramson, S. et al., "Modes of action of aspirin-like drugs", Proc. Natl. Acad. Sci. USA (1985) 82:7227-7231
	Baeuerle, P.A., "The Inducible Transcription Activator NF- κ B: Regulation by Distinct Protein Subunits", Biochimica Biophysica. Acta. (1991) 1072:63-80

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 18 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Baldwin, A.S., "Two Transcription Factors, NF- κ B and H2TF1, Interact With a Single Regulatory Sequence In the Class I major Histocompatibility Complex Promoter", Proc. Natl. sci. USA, (1988) 85:723-727
	Beutler, B. et al., "Control of Cachectin (Tumor Necrosis Factor) Synthesis: Mechanisms of Endotoxin Resistance", Science (1986) 232:977-980
	Bielinska, A. et al., "Regulation of Gene Expression with Double-Stranded Phosphorothioate Oligonucleotides", Science (1990) 250:997-1000
	Brini, A.T., et al., "Cyclosporin A inhibits induction of IL-2 receptor α chain expression by affecting activation of NF- κ B-like factor(s) in cultured human T lymphocytes", Eur. Cytokine Net. (1990) 1:131-139
	Chedid, M. And Mizel, S.B., "Involvement of Cyclic AMP-Dependent Protein Kinases in the Signal Transduction Pathway for Interleukin-1" Molecular And Cellular Biology (1990) 10:3824-3827

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 19 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Colston, K. et al. "1, 25-Dihydroxyvitamin D3 and Malignant Melanoma: The Presence of Receptors and Inhibition of Cell Growth in Culture" Endocrinology (1981) 108:1083-1086
	Devary, Y. et al., "NF- κ B Activation by Ultraviolet Light Not Dependent on a Nuclear Signal" Science (1993) 261:1442-1445
	Dew, MJ, "Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth" British Medical Journal (1983) 287:23-24
	Dobrilla, G. et al., "Is Ethanol Metabolism Affected by Oral Administration of Cimetidine and Ranitidine at Therapeutic Doses?" Hepato-gastroenterol (1984) 31:35-37
	Eck, S.D. et al., "Inhibition of Phorbol Ester-Induced Cellular Adhesion by Competitive Binding of NF- κ B In Vivo" Molecular and Cellular Biology (1993) 13:6530-6536

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 20 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Edbrooke, M.R. et al., "Identification of <i>cis</i> -Acting Sequences Responsible for Phorbol Ester Induction of Human Serum Amyloid A Gene Expression via a Nuclear Factor κ B-Like Transcription Factor" Molecular and Cellular Biology (1989) 9:1908-1916
	Emmel, E.A. et al., "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation" Science (1989) 246:1617-1620
	Giri, J.G. et al., "Interleukin 1-Mediated Induction of κ -Light Chain Synthesis And Surface Immunoglobulin Expression of Pre-B Cells" The Journal of Immunology (1984) 132:223-228
	Gray, T.K. et al., "17 β -Estradiol acts directly on the clonal osteoblastic cell line UMR106" Proc. Natl. Acad. Sci. USA (1987) 84:6267-6271
	Griffith [1], B.P., et al., "Targeted blood levels of cyclosporine for cardiac transplantation" J. Thorac Cardiovasc Surg (1984) 88:952-957
	Griffith [2], B.P., et al., "Cardiac Transplantation with Cyclosporin A and Prednisone" Ann. Surg. (1982) 196:324-329

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicants

David Baltimore et al.

Filing Date

January 4, 2002

Page 21 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Hahn, E.O. et al., "Effect of Cortisone on Acute Streptococcal Infections And Post-Streptococcal Complications ¹ " Streptococcal Disease Laboratory (1950) pp. 274-281
	Holick, M.F. et al., "Identification of 1,25-Dihydroxycholecalciferol, a Form of Vitamin D ₃ Metabolically Active in the Intestine" Proc. Nat. Acad. Sci. USA (1971) 68:803-804
	Hoyos, B. Et al., "Kappa B-Specific DNA Binding Proteins: Role in the Regulation of Human Interleukin-2 Gene Expression" Science (1989) 244:457-460
	Jones, A.W., "Elimination Half-life of Methanol During Hangover" Pharmacology & Toxicology (1987) 60:217-220
	Kohase, M. et al., "Dexamethasone Inhibits Feedback Regulation of the Mitogenic Activity of Tumor Necrosis Factor, Interleukin-1, and Epidermal Growth Factor in Human Fibroblasts" Journal of Cellular Physiology (1987) 132:271-278
	Koizumi, T. et al., "Inhibitors of IL-2 Production and IL-2 Receptor Expression in Human Leukemic T-Cell Line, Jurkat ¹ " Cellular Immunology (1986) 103:469-475

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicants

David Baltimore et al.

Filing Date

January 4, 2002

Page 22 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Kovacs, E.J., et al., "Differential Inhibition of IL-1 and TNF- α mRNA Expression By Agents Which Block Second Messenger Pathways In Murine Macrophages" ¹ The Journal of Immunology (1988) 141:3101-3105
	Krönke, M. et al., "Cyclosporin A Inhibits T-cell Growth Factor Gene Expression At the Level of mRNA Transcription", Proc. Natl. Acad. Sci. USA (1984) 81:5214-5218
	Lawson, D.E.M., et al., "Identification of 1,25-Dihydroxycholecalciferol, a New Kidney Hormone controlling Calcium Metabolism" Nature (1971) 230:228-230
	Lemire, J.M., et al., "1,25-Dihydroxyvitamin D ₃ Suppresses Human T Helper/Inducer Lymphosyte Activity in Vitro" ¹ The Journal of Immunology (1985) 134:3032-3035
	Lemire [2], J.M. et al., "1 α ,25-Dihydroxyvitamin D ₃ Suppresses Proliferation and Immunoglobulin Production by Normal Human Peripheral Blood Mononuclear Cells", J. Clin. Invest. (1984) 74:657-661

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 23 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Lipsky, P.E. et al., "The Role of Interleukin 1 in Human B Cell Activation: Inhibition of B Cell Proliferation and the Generation of Immunoglobulin-Secreting Cells By An Antibody Against Human Leukocytic Pyrogen ¹ " The Journal of Immunology (1983) 130:2708-2714
	Mannel, D.N., et al., "Inhibition of Nonspecific Tumocidal Activity by Activated Macrophages with Antiserum Against a Soluble Cytotoxic Factor" Infection And Immunity (1981) 33:156-164
	Manolagas [1], S.C. et al., "The Antiproliferative Effect of Calcitriol on Human Peripheral Blood Mononuclear Cells" Journal of Clinical Endocrinology and Metabolism (1986) 63:394-400
	Manolagas [2], S.C. et al., Estrogen, Cytokines, and the Control of Osteoclast Formation and Bone Resorption In Vitro and In Vivo" Osteoporosis Int (1993) Suppl. 1:S114-116

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 24 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
			□ □			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Matthews [1], N., "Human Monocyte Killing of Tumor Cells: Contribution of an Extracellular Cytotoxin" Department of Medical Microbiology (1982) 721-729
	Matthews [2], N., "Effect on human monocyte killing of tumour cells of antibody raised against an extracellular monocyte cytotoxin" Immunology (1983) 48:321-327
	Meichle A. et al., "Protein Kinase C-independent Activation of Nuclear Factor κB by Tumor Necrosis Factor" The Journal of Biological Chemistry (1990) 265:8339-8343
	Mihm [1], S. And Droege, W., "Intracellular Glutathione Level Controls DNA-Binding Activity of NF-κB-Like Protein(s)" Institute of Immunology and Genetics, German Cancer Research Center, S.A.311
	Mihm [2], S. et al., "Inhibition of HIV-1 replication and NF-κB activity by cysteine and cysteine derivatives" AIDS (1991) 5:497-503

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 25 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Miller, H.R. et al., "Reduction of Nonspecific Fluorescence in Respiratory Specimens By Pretreatment with N-Acetylcysteine" Journal of Clinical Microbiology (1986) 24:470-471
	Mukaida, N. et al., "Novel Mechanism of Glucocorticoid-Mediated Gene Repression" The Journal of Biological Chemistry (1994) 269:13289-13295
	Nagasawa, K. et al., "Inductio of Human Malignanat T-Lymphoblastic Cell Lines MOLT-3 and Jurkat by 12-O-Tetradecanoylphorbol-13-Acetate: Ciochemical, Physical, and Morphological Characterization" Journal of Cellular Physiology (1981) 109:181-192
	Norman, A.W. et al., "1,25-Dihydroxycholecalciferol: Identification of the Proposed Active Form of Vitamin D ₃ in the Intestine" Science (1971) 173:51-54
	Osborn, L. et al., "Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κ B" Proc. Natl. Acad. Sci. USA (1989) 86:2336-2340

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 26 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Provvedini, D.M. et al., "1,25-Dihydroxyvitamin D ₃ Receptors in Human Leukocytes" Science (1983) 221:1181-1183
	Reed, J.C. et al., "Effect of Cyclosporin A and Dexamethasone on Interleukin 2 Receptor Gene Expression ¹ " The Journal of Immunology (1986) 137:150-154
	Reed [2], J.C. et al., "Regulation of c-myc mRNA levels in normal human lymphocytes by modulators of cell proliferation" Proc. Natl. Acad. Sci. USA (1985) 82:4221-4224
	Rigby [1], W.F.C. et al., "Regulation of Lymphokine Production and Human T Lymphocyte Activation by 1, 25-Dihydroxyvitamin D ₃ " J. Clin. Invest. (1987) 79:1659-1664
	Rigby [2], W.F.C. et al., "The Effects of 1,25-Dihydroxyvitamin D ₃ on Human T Lymphocyte Activation and Proliferation: A cell cycle analysis" The Journal of Immunology (1985) 135:2279-2286
	Roederer, M. et al., "Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine" Proc. Natl. Acad. Sci. USA (1990) 87:4884-4888

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Applicants

David Baltimore et al.

Filing Date

January 4, 2002

Page 27 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Rovera, G. et al., "Induction of Differentiation in Human Promyelocytic Leukemia Cells by Tumor Promoters" Science (1979) 204:868-870
	Ruben and Rosen, "Suppression of Signals Required for Activation of Transcription Factor NF- κ B in Cells Constitutively Expressing the HTLV-I Tax Protein" The New Biologist (1990) 2:894-902
	Saito [Article], Y. et al., "Possible involvement of a novel protease in neurite outgrowth of PC12 cells" Neuroscience Research, Suppl. 13 (1990) S97-S101
	Saito [1], Y. et al., "Enhancement of neurite outgrowth in PC12h cells by a protease inhibitor" Neuroscience Letters (1988) 89:102-107
	Saito [2], Y. et al., "The Neurite-Initiating Effect of a Tripeptide Aldehyde Protease Inhibitor on PC12h Cells" J. Biochem. (1989) 106:1035-1040

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicants

David Baltimore et al.

Filing Date
January 4, 2002

Page 28 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Scheinman, R. et al., "Characterization of Mechanisms Involved In Transrepression of NF- κ B by Activated Glucocorticoid Receptors", Molecular and Cellular Biology (1995) 15:943-953
	Schmidt, A. et al., "Inducible Nuclear Factor Binding to the κ B Elements of the Human Immunodeficiency Virus Enhancer in T Cells Can Be Blocked by Cyclosporin A in a Signal-Dependent Manner", Journal of Virology (1990) 64:4037-4041
	Schreck [1], R. et al., "Dithiocarbamates as Potent Inhibitors of Nuclear Factor κ B Activation in Intact Cells" J. Exp. Med. (1992) 175:1181-1194
	Schreck [2], R. et al., "Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF- κ B transcription factor and HIV-1" The EMBO Journal (1991) 10:2247-2258
	Semmler, E.J. et al., "The Synthesis of 1 α ,25-Dihydroxycholecalciferol – A Metabolically Active Form of Vitamin D ₃ " Tetrahedron Letters No. 40 (1972) 4147-4150

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 29 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation
							Yes

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Shirakawa and Mizel, "In Vitro Activation and Nuclear Translocation of NF- κ B Catalyzed by Cyclic AMP-Dependent Protein Kinase and Protein Kinase C", Molecular and Cellular Biology (1989) 9:2424-2430
	Siebenlist, U. et al., "Promoter Region of Interleukin-2 Gene Undergoes Chromatin Structure Changes and Confers Inducibility on Chloramphenicol Acetyltransferase Gene during Activation of T Cells" Molecular and Cellular Biology (1986) 6:3042-3049
	St. Ledger, et al., "Factors Associated With Cardiac Mortality In Developed Countries With Particular Reference To The Consumption of Wine", Public Health, The Lancet (1979) 1017-1020
	Staal, F.J.T. et al., "Intracellular Thiols Regulate Activation of Nuclear Factor κ B and Transcription of Human Immunodeficiency Virus", Proc. Natl. Acad. Sci. USA (1990) 87:9943-9947
	Tanaka, H. et al., "Sequence-specific interaction of α - β -anomeric couple-stranded DNA with the p50 subunit of NF- κ B: application to the decoy approach" Nucleic Acids Research (1994) 22:3069-3074

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicants

David Baltimore et al.

Filing Date

January 4, 2002

Page 30 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Thévenin, C. et al., "Induction of Nuclear Factor- κ B and the Human Immunodeficiency Virus Long Terminal Repeat by Okadaic Acid, a Specific Inhibitor of Phosphatases 1 and 2A" The New Biologist (1990) 2:793-800
	Tong-Starksen, S.E. et al., "Signaling Through T Lymphocyte Surface Proteins, TCR/CD3 And CD28, Activates The HIV-1 Long Terminal Repeat" The Journal of Immunology (1989) 142:702-707
	Tracey, K.J. et al., "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia" Nature (1987) 330:662-664
	Tsoukas, C.D. et al., "1,25-Dihydroxyvitamin D ₃ : A Novel Immunoregulatory Hormone" Science (1984) 224:1438-1440
	Waage and Bakke, "Glucocorticoids suppress the production of tumour necrosis factor by lipopolysaccharide-stimulated human monocytes" Immunology (1988) 63:299-302

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 31 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Weissmann, G., "Aspirin: After more than 200 years, the mechanisms by which this venerable drug and its relatives achieve their wide range of effects have yet to be fully elucidated" Scientific American Journal (1991) pp. 84-90
	Physicians' Desk Reference 1970 24 th Edition
	Physicians' Desk Reference 1980 34 th Edition
	Physicians' Desk Reference 1985 39 th Edition

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicants

David Baltimore et al.

Filing Date
January 4, 2002

Page 32 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation
							Yes
							No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	June 28, 2007 Deposition of Lynn Corcoran, Ph.D., Pages 1-109, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	July 10, 2007 Deposition of Roger Gregoire Clerc, Ph.D., Pages 1-201, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	August 7, 2007 Videotaped Deposition of Louis M. Staudt, M.D., Ph.D., Pages 1-275, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	August 20, 2007 Videotaped Deposition of Patrick A. Baeuerle, Ph.D., Vol. I-II, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	June 29, 2007 Wyeth's Response To Ariad's First Set Of Interrogatories (Nos. 1-25), Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 33 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	July 9, 2007 Ariad And The Institutions' Responses And Objections To Amgen Entities' Second Set Of Interrogatories, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	August 17, 2007 Wyeth's Supplemental Responses To Ariad's First Set Of Interrogatories (Nos. 1-25), Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	September 10, 2007 Wyeth's Second Set of Supplemental Responses To Ariad's First Set Of Interrogatories (Nos. 1-25), Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	Annual Meeting, J. Am. Med. Assoc. (1963) 183:166-169
	Baeuerle and Baltimore, "IκB: A Specific Inhibitor of the NF-κB Transcription Factor", Science (1988a) 242:540-546
	Baeuerle and Baltimore, "Activation of DNA-Binding Activity in an Apparently Cytoplasmic Precursor of the NF-κB Transcription Factor", Cell (1988b) 53:211-217

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 34 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation
							Yes
							No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Baeuerle and Baltimore, "Phorbol-ester-induced Activation of the NF- κ B Transcription Factor Involves Dissociation of an Apparently Cytoplasmic NF- κ B/Inhibitor Complex", Cold Spring Harbor Symposia (1988c) LIII:789-798
	Baltimore and Sharp, "Binding of a Nuclear Factor to a Regulatory Sequence in the Promoter of The Mouse H-2K ^b Class I Major Histocompatibility Gene", Molecular and Cellular Biology (1987) 7:305-313
	Baltimore, D., "Intracellular immunization", Nature (1988) 335:395-396
	Banerji, S.S. et al., "The Immunosuppressant FK-506 Specifically Inhibits Mitogen-Induced Activation of the Interkeukin-2 Promoter and the Isolated Enhancer Elements NFIL-2A and NF-AT1", Molecular and Cellular Biology (1991) 11:4074-4087
	Blanar, M.A. et al., "A gamma-interferon-induced factor that binds the interferon response sequence of the MHC class I gene, H-2K ^b ", The EMBO Journal (1989) 8:1139-1144

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office				Atty. Docket No. 75723-ZB/JPW/GJG	Serial No. 10/037,415
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)						Applicants David Baltimore et al.	
						Filing Date January 4, 2002	Page 35 of 50
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
FOREIGN PATENT DOCUMENTS							
	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Bohnlein E. et al., "The Same Inducible Nuclear Proteins Regulates Mitogen Activation of Both the Interleukin-2 Receptor-Alpha Gene and Type 1 HIV", Cell (1988) 53:827-836					
		Clouse, K.A. et al., "Monokine Regulation of Human Immunodeficiency Virus-1 Expression in a Chronically Infected Human T Cell Clone", The Journal of Immunology (1989) 142:431-438					
		Collart, M.A. et al., "Modulations of Functional Activity in Differentiated Macrophages are Accompanied by Early And Transient Increase or Decrease in c-FOS Gene Transcription", The Journal of Immunology (1987) 139:949-955					
		Collart, M.A. et al., "Regulation of Tumor Necrosis Factor Alpha Transcription in Macrophages: Involvement of Four κB-Like Motifs and of Constitutive and Inducible Forms of NF-κB", Molecular and Cellular Biology (1990) 10:1498-1506					
		Cross, S.L. et al., "Functionally Distinct NF-κB Binding Sites in the Immunoglobulin κ and IL-2 Receptor α Chain GEnes", Science (1989) 244:466-469					
EXAMINER		DATE CONSIDERED					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002 Page 36 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Davis, N. et al., "Rel-Associated pp40: An Inhibitor of the Rel Family of Transcription Factors", Science (1991) 253:1268-1271
	Dew, M.J. et al., "Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth", British Medical Journal (1983) 287:23-24
	Dofferhoff, A.S.M., et al., "Effects of Different Types and Combinations of Antimicrobial Agents on Endotoxin Release from Gram-negative Bacteria: An In-Vitro and In-Vivo Study", Scandinavian Journal of Infectious Diseases (1991) 23:745-754
	Fan, Chen-Ming and Maniatis, T., "Two different virus-inducible elements are required for human β -interferon gene regulation", The EMBO Journal (1989) 8:101-110
	Fan, Chen-Ming and Maniatis, T., "A DNA-binding protein containing two widely separated zinc finger motifs that recognize the same DNA sequence", Genes and Development (1990) 4:29-42

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 37 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Fan, Chen-Ming and Maniatis, T., "Generation of p50 subunit of NF- κ B by processing of p105 through an ATP-dependent pathway", Nature (1991) 354:395-398
	Friedman, A.D. et al., "Expression of a truncated viral trans-activator selectively impedes lytic infection by its cognate virus", Nature (1988) 335:452-454
	Gehrt, A. Et al., "Cycloepoxydon, 1-Hyrdoxy-2-hydroxymethyl-3-pent-1-enylbenzene and 1-Hydroxy-2-hydroxymethyl-3-pent-1, 3-dienylbenzene, New Inhibitors of Eukaryotic Signal Transduction", The Journal of Antibiotics (1998) 51:455-463
	Goldfeld, A.E. and Maniatis, T., "Coordiante viral induction of tumor necrosis factor α and interferon β cells and monocytes", Proc. Natl. Acad. Sci. USA (1989) 86:1490-1494
	Goldfeld, A. E. et al., "Human tumor necrosis factor α gene regulation by virus and lipopolysaccharide", Proc. Natl. Acad. Sci. USA (1990) 87:9769-9773

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 38 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Goodbourn, S. And Maniatis, T., "Overlapping positive and negative regulatory domains of the human β -interferon gene", Proc. Natl. Acad. Sci. USA (1988) 85:1447-1451
	Haskill, S. et al., "Characterization of an Immediate-Early Gene Induced in Adherent Monocytes That Encodes I κ B-like Activity", Cell (1991) 65:1261-1289
	Horuk, R., "A rapid and direct method for the detection and quantification of interleukin-1 receptors using 96 well filtration plates", Journal of Immunological Methods (1989) 119:255-258
	Hurley, J.C. et al., "Antibiotic-Induced Release of Endotoxin in Chronically Bacteriuric Patients", Antimicrobial Agents and Chemotherapy (1991) 35:2388-2394
	Keller, A.D. and Maniatis, T., "Identification of an inducible factor that binds to a positive regulatory element of the human β -interferon gene", Proc. Natl. Acad. Sci. USA (1988) 85:3309-3313
	Kerr, L.D. et al., "The Rel-associated pp40 protein prevents DNA binding of Rel and NF- κ B: relationship with I κ B β and regulation by phosphorylation", Genes and Development (1991) 5:1464-1476

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Applicants
David Baltimore et al.Filing Date
January 4, 2007

Page 39 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation
							Yes
							No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	St. Ledger, A.S. et al., "Factors Associated With Cardiac Mortality In Developed Countries With Particular Reference To The Consumption of Wine", The Lancet (1979) 1017-1020
	Lenardo, M. et al., "Protein-Binding Sites in Ig Gene Enhancers Determine Transcriptional Activity and Inducibility", Science (1987) 236:1573-1577
	Lenardo, M.J. et al., "NF-κB protein purification from bovine spleen: Nucleotide stimulation and binding site specificity", Proc. Natl. Acad. Sci. USA (1988) 85:8825-8829
	Lenardo, M.J. et al., "The Involvement of NF-κB in β-Interferon Gene Regulation Reveals Its Role as Widely Inducible Mediator of Signal Transduction", Cell (1989) 57:287-294
	Leung, K. and Nabel, G., "HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-κB-like factor", Nature (1988) 333:776-778

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 40 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Logeat, F. et al., "Inhibition of transcription factors belonging to the rel/NF- κ B family by a transdominant negative mutant", The EMBO Journal (1991) 10:1827-1832
	Mauxion, F. et al., "Comparison of constitutive and inducible transcriptional enhancement mediated by κ B-related sequences: Modulation of activity in B cells by human T-cell leukemia virus type I tax gene", Proc. Natl. Acad. Sci. USA (1991) 88:2141-2145
	Mauxion, F. And Sen, R., "Alteration of a Single Nucleotide Allows Efficient Binding of H2TF1/KBF1 to the Immunoglobulin κ Enhancer B Motif", Molecular and Cellular Biology (1989) 9:3548-3552
	Mustafa, M.M. et al., "Increased Endotoxin and Interleukin-1 β Concentrations in Cerebrospinal Fluid of Infants with Coliform Meningitis and Ventriculitis Associated with Intraventricular Gentamicin Therapy", The Journal of Infectious Diseases (1989) 160:891-895

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
75723-ZB/JPW/GJGSerial No.
10/037,415INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 41 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Nabel, G. and Baltimore, D., "An inducible transcription factor activates expression of human immunodeficiency virus in T cells", Nature (1987) 326:711-713
	Nelsen, B. et al., "The NF- κ B-Binding Site Mediates Phorbol Ester-Inducible Transcription in Nonlymphoid Cells", Molecular and Cellular Biology (1988) 8:3526-3531
	Rigby, W.F.C. et al., "Inhibition of T Lymphocyte Mitogenesis by 1,25-Dihydroxyvitamin D ₃ (Calcitriol)", J. Clin. Invest. (1984) 74:1451-1455
	Rigby, W.F.C. et al., "The Effects of 1,25-Dihydroxyvitamin D ₃ on Human T Lymphocyte Activation And Proliferation: A Cell Cycle Analysis", The Journal of Immunology (1985) 135:2279-2286
	Ruben, S. et al., "Cellular Transcription Factors and Regulation of IL-2 Receptor Gene Expression by HTLV-1 tax Gene Product", Science (1988) 241:89-92

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 42 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Schmitz, M.F., et al., "Proteins controlling the nuclear uptake of NF- κ B, Rel and dorsal", Trends in Cell Biology (1991) 1:130-137
	Schreck, R. and Baeuerle, P., "A role for oxygen radicals as second messengers", Trends in Cell Biology (1991) 1:39-42
	Sen, R. and Baltimore, D., "Multiple Nuclear Factors Interact with the Immunoglobulin Enhancer Sequences", Cell (1986) 46:705-716
	Sen, R. and Baltimore, D., "Inducibility of κ Immunoglobulin Enhancer-Binding Protein NF- κ B by a Posttranslational Mechanism", Cell (1986) 47:921-928
	Shenep, J.L. and Mogan, K.A., "Kinetics of Endotoxin Release During Antibiotic Therapy For Experimental Gram-Negative Bacterial Sepsis", The Journal of Infectious Diseases (1984) 150:380-388

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			Atty. Docket No. 75723-ZB/JPW/GJG		Serial No. 10/037,415	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)					Applicants David Baltimore et al.			
					Filing Date January 4, 2002		Page 43 of 50	
U.S. PATENT DOCUMENTS								
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate	
FOREIGN PATENT DOCUMENTS								
	Document Number	Date	Country	Class	Subclass	Translation		
						Yes	No	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	Scott, J.K. and Smith, G.P., "Searching for Peptide Ligands with an Epitope Library", Science (1990) 249:386-390							
	Tomita, T. et al., "Suppressed Severity of Collagen-Induced Arthritis By In Vivo Transfection of Nuclear Factor κ B Decoy Oligodeoxynucleotides As A Gene Therapy", Arthritis & Rheumatism (1999) 42:2532-2542							
	Yu, Xiao-Peng et al., "down-regulation of NF- κ B protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D ₃ ", Proc. Natl. Acad. Sci. USA (1995) 92:10990-10994							
	Zabel, U., and Baeuerle, P.A., "Purified Human I κ B Can Rapidly Dissociate the Complex of the NF- κ B Transcription Factor with Its Cognate DNA", Cell (1990) 61:255-265							
	Zinn, K. et al., "Identification of Two Distinct Regulatory Regions Adjacent to the Human β -Interferon Gene", Cell (1983) 34:865-879							
EXAMINER		DATE CONSIDERED						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 45 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number							Date	Name	Class	Subclass	Filing Date if Appropriate
1	4	6	8	4	6	2	3	8/4/87	Lerrick et al.				
2	5	6	5	8	8	0	3	8/19/97	Kuo				
3	5	6	9	8	4	1	9	12/16/97	Wolpe et al.				

FOREIGN PATENT DOCUMENTS

		Document Number		Date	Country	Class	Subclass	Translation					
								Yes					
4	8	9	0	7	6	1	4	8/24/89	PCT				No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

5	Beutler, B. et al., "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin", Science (1985) 229:869-871
6	Beutler, B. and Cerami, A., "Cachectin: More Than A Tumor Necrosis Factor", The New England Journal of Medicine (1987) 316:379-385
7	Beutler, B. and Cerami, A., "Tumor Necrosis, Cachexia, Shock, And Inflammation: A Common Mediator", Ann. Rev. Biochem. (1988) 57:505-18
8	Blasco, R. et al., "Variable and Constant Regions in African Swine Fever Virus DNA", Virology (1989) 168:330-338
9	Brady, J. et al., "Interaction between two transcriptional control sequences required for tumor-antigen-mediated simian virus 40 late gene expression", Proc. Natl. Acad. Sci. USA (1985) 82:7299-7303

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Patent and Trademark Office				75723-ZB/JPW/GJG	10/037,415
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants David Baltimore et al.	
				Filing Date January 4, 2002	Page 46 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation
						Yes
						No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

10	Brady, J. and Khoury, G., "trans Activation of the Simian Virus 40 Late Transcription Unit by T-Antigen", Molecular and Cellular Biology (1985) 5:1391-1399				
11	Enjuanes, L. et al., "Titration of African Swine Fever (ASF) Virus", J. Gen. Virol. (1976) 32:471-477				
12	Enjuanes, L. et al., "Isolation and Properties of the DAN of African Swine Fever (ASF) Virus", J. Gen. Virol. (1976) 32:479-492				
13	Fendly, B.M. et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor", Hybridoma (1987) 6:359-370				
14	Israël, A. et al., "A common positive trans-acting factor binds to enhancer sequence in the promoters of mouse H-2 and β_2 -microglobulin genes", Proc. Natl. Acad. Sci. USA (1987) 84:2653-2657				

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Applicants

David Baltimore et al.

Filing Date

January 4, 2002

Page 47 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

15	Israël, A. et al., "TNF stimulates expression of mouse MHC class I genes by inducing an Nf κ B-like enhancer binding activity which displaces constitutive factors", The EMBO Journal (1989) 8:3793-3800
16	Lenardo, M.J. and Baltimore, D., "NF- κ B: A Pleiotropic Mediator of Inducible and Tissue-Specific Gene Control", Cell (1989) 58:227-229
17	Meager, A. et al., "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)", Hybridoma (1987) 6:305-311
18	Mercola, M. et al., "Immunoglobulin Heavy-Chain Enhancer Requires One or More Tissue-Specific Factors", Science (1985) 227:266-270
19	Rothlein, R. et al., "Induction of Intercellular Adhesion Molecule 1 on Primary And Continuous Cell Lines By Pro-Inflammatory Cytokines", The Journal of Immunology (1988) 141:1665-1669

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
 (Use several sheets if necessary)

Applicants
David Baltimore et al.

Filing Date
January 4, 2002 Page 48 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

20	Schöler, H.R. and Gruss, P., "Specific Interaction between Enhancer-Containing Molecules and Cellular Components", Cell (1984) 36:403-411
21	Singh, H. et al., "A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes", Nature (1986) 319:154-158
22	September 13, 2007 Order, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
23	September 20, 2007 Amgen Entities' Amended Response And Objections To Ariad's Interrogatory No. 12, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
24	September 21, 2007 Wyeth's Third Set of Supplemental Responses And Objections To Ariad's First Set of Interrogatories (Nos. 1-25), Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants
David Baltimore et al.Filing Date
January 4, 2002

Page 49 of 50

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

25	September 24, 2007 Answer To Amended Complaint, Amended Counterclaim and Demand For Jury Trial, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
26	September 26, 2007 Deposition of David Baltimore including Exhibits 169-178, 1008-1016, 1, 11, 12, 57, 146, 1002 and 1004, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
27	October 3, 2007 Videotaped Deposition of Tom Maniatis, Ph.D. including Exhibits 1, 11-12, 31-32, 35-36, 78, 179-189 and 191-194, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
28	October 4, 2007 continued Videotaped Deposition of Tom Maniatis, Ph.D. including Exhibits 1, 11-12, 31-32, 35-36, 78, 195-196, 1017-1022, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Patent and Trademark Office

75723-ZB/JPW/GJG 10/037,415

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicants

David Baltimore et al.

Filing Date

January 4, 2002

Page 50 of 50

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	29	October 9, 2007 Amgen Entities' Reply to Ariad, Harvard, MIT, And Whitehead's Amended Counterclaim, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	30	October 9, 2007 Wyeth's Reply To Ariad Pharmaceuticals, Inc., Massachusetts Institute of Technology, The President And Fellows of Harvard College, And The Whitehead Institute for Biomedical Research's Amended Counterclaim, Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT
	31	October 31, 2007 Wyeth's Fourth Set of Supplemental Responses And Objections To Ariad's First Set of Interrogatories (Nos. 1-25), Amgen, Inc. et al. v. Ariad Pharmaceuticals, Inc. et al., D. Del. Civil Action No. 06-259-MPT

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.